Advertisement

 

 

Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation.

Patient-provider discordance between global assessments of disease activity in rheumatoid arthritis: a comprehensive clinical evaluation.
Author Information (click to view)

Challa DN, Kvrgic Z, Cheville AL, Crowson CS, Bongartz T, Mason TG, Matteson EL, Michet CJ, Persellin ST, Schaffer DE, Muskardin TLW, Wright K, Davis JM,


Challa DN, Kvrgic Z, Cheville AL, Crowson CS, Bongartz T, Mason TG, Matteson EL, Michet CJ, Persellin ST, Schaffer DE, Muskardin TLW, Wright K, Davis JM, (click to view)

Challa DN, Kvrgic Z, Cheville AL, Crowson CS, Bongartz T, Mason TG, Matteson EL, Michet CJ, Persellin ST, Schaffer DE, Muskardin TLW, Wright K, Davis JM,

Advertisement

Arthritis research & therapy 2017 09 2619(1) 212 doi 10.1186/s13075-017-1419-5
Abstract
BACKGROUND
Discordance between patients with rheumatoid arthritis (RA) and their rheumatology health care providers is a common and important problem. The objective of this study was to perform a comprehensive clinical evaluation of patient-provider discordance in RA.

METHODS
A cross-sectional observational study was conducted of consecutive RA patients in a regional practice with an absolute difference of ≥ 25 points between patient and provider global assessments (possible points, 0-100). Data were collected for disease activity measures, clinical characteristics, comorbidities, and medications. In a prospective substudy, participants completed patient-reported outcome measures and underwent ultrasonographic assessment of synovial inflammation. Differences between the discordant and concordant groups were tested using χ(2) and rank sum tests. Multivariable logistic regression was used to develop a clinical model of discordance.

RESULTS
Patient-provider discordance affected 114 (32.5%) of 350 consecutive patients. Of the total population, 103 patients (29.5%) rated disease activity higher than their providers (i.e., ‘positive’ discordance); only 11 (3.1%) rated disease activity lower than their providers and were excluded from further analysis. Positive discordance correlated with negative rheumatoid factor and anticyclic citrullinated peptide antibodies, lack of joint erosions, presence of comorbid fibromyalgia or depression, and use of opioids, antidepressants, or anxiolytics, or fibromyalgia medications. In the prospective study, the group with positive discordance was distinguished by higher pain intensity, neuropathic type pain, chronic widespread pain and associated polysymptomatic distress, and limited functional health status. Depression was found to be an important mediator of positive discordance in low disease activity whereas the widespread pain index was an important mediator of positive discordance in moderate-to-high disease activity states. Ultrasonography scores did not reveal significant differences in synovial inflammation between discordant and concordant groups.

CONCLUSIONS
The findings provide a deeper understanding of patient-provider discordance than previously known. New insights from this study include the evidence that positive discordance is not associated with unrecognized joint inflammation by ultrasonography and that depression and fibromyalgia appear to play distinct roles in determining positive discordance. Further work is necessary to develop a comprehensive framework for patient-centered evaluation and management of RA and associated comorbidities in patients in the scenario of patient-provider discordance.

Submit a Comment

Your email address will not be published. Required fields are marked *

four × 2 =

[ HIDE/SHOW ]